BioCentury
ARTICLE | Company News

miRagen, t2cure deal

December 6, 2010 8:00 AM UTC

t2cure granted miRagen exclusive, worldwide rights to the technology and IP related to the in vivo use of microRNA 92 (miR-92). t2cure retains the rights to use modulators of miR-92 for ex-vivo treatm...